Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis

Next Previous
Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lirentelimab (Primary)
  • Indications Eosinophilic gastroenteritis
  • Focus Therapeutic Use
  • Acronyms ENIGMA
  • Sponsors Allakos

Most Recent Events

  • 27 Oct 2021 Results of an analysis compared symptom responses of patients with new diagnoses (de novo patients) with those of patients with prior diagnoses of EG and/or EoD to lirentelimab in ENIGMA and an open-label extension study.presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021
  • 23 May 2021 Results of an analysis assessing the endoscopic findings in subjects with EG and to compare them to those of symptomatic individuals without EG using screening data from a randomized, controlled trial of lirentelimab (AK002) presented at the Digestive Disease Week 2021
  • 23 May 2021 Results of analysis assessing rates of diagnosis and define number of biopsies required to optimize EG/EoD detection using screening data from this trial presented at the Digestive Disease Week 2021

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top